Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third ...

Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma. Differences in age of diagnosis and survival period for individuals of ...

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICMLPresentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June ...

Patterns and clinical significance of high-risk secondary cytogenetic abnormalities at first relapse in multiple myeloma.

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

Facing a rare cancer and mounting medical costs, Gregory Morgan is turning to his community for support in his fight for life ...

Facing a rare cancer and mounting medical costs, Gregory Morgan is turning to his community for support in his fight for life.

InnoCare gets China NMPA approval for Minjuvi in combo with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma: Beijing, China Friday, May 23, 2025, 13:00 ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...